L-carnitine supplementation in dialysis: treatment in quest of disease.

摘要: L-Carnitine (LC) administration has been recommended for specific indications in dialysis patients, including epoetin-resistant anemia, intradialytic hypotension, cardiomyopathy, fatigue, muscle weakness, and exercise performance; it may ameliorate insulin resistance, inflammation, protein wasting. Use of LC anemia hypotension approved reimbursement by the Centers Medicare Medicaid Services. Yet, data to support these recommendations are inadequate have not bolstered over several decades. continues appeal nephrologists because its use patients an attractive rationale, addresses problems that persist despite dialysis, is safe, existing literature does refute use. Nevertheless, definitive trials justify conducted increasingly unlikely be funded. In era shrinking resources bundling services, will, appropriately, diminish.